VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update
VolitionRx Limited (NYSE AMERICAN: VNRX) has scheduled its First Quarter 2025 Earnings Conference Call and Business Update for Friday, May 16, 2025, at 8:30 a.m. U.S. Eastern Time. The call will be hosted by Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (President and Group CEO), and Terig Hughes (Group CFO).
The conference call will discuss Q1 2025 financial and operating results, recent important events, and upcoming milestones. Participants can join via multiple channels including U.S. & Canada toll-free (1-877-407-9716), U.K. toll-free (0 800 756 3429), or international dial-in (1-201-493-6779). A live audio webcast will be available, and a replay will be accessible until May 30, 2025.
VolitionRx Limited (NYSE AMERICAN: VNRX) ha programmato la sua Conferenza Telefonica sui Risultati del Primo Trimestre 2025 e l'Aggiornamento Aziendale per venerdì 16 maggio 2025, alle 8:30 a.m. ora della costa orientale degli Stati Uniti. La chiamata sarà condotta da Louise Batchelor (Responsabile Marketing e Comunicazione del Gruppo), Cameron Reynolds (Presidente e Amministratore Delegato del Gruppo) e Terig Hughes (Direttore Finanziario del Gruppo).
Durante la conferenza telefonica verranno discussi i risultati finanziari e operativi del primo trimestre 2025, gli eventi recenti di rilievo e i prossimi traguardi. I partecipanti potranno collegarsi attraverso vari canali, inclusi i numeri verdi per Stati Uniti e Canada (1-877-407-9716), Regno Unito (0 800 756 3429) o tramite chiamata internazionale (1-201-493-6779). Sarà disponibile una diretta audio in webcast e una registrazione sarà accessibile fino al 30 maggio 2025.
VolitionRx Limited (NYSE AMERICAN: VNRX) ha programado su Conferencia Telefónica de Resultados del Primer Trimestre de 2025 y Actualización Empresarial para el viernes 16 de mayo de 2025, a las 8:30 a.m., hora del este de EE.UU.. La llamada será dirigida por Louise Batchelor (Directora General de Marketing y Comunicaciones del Grupo), Cameron Reynolds (Presidente y CEO del Grupo) y Terig Hughes (Director Financiero del Grupo).
En la conferencia se discutirán los resultados financieros y operativos del primer trimestre de 2025, eventos importantes recientes y próximos hitos. Los participantes podrán unirse a través de varios canales, incluyendo números gratuitos para EE.UU. y Canadá (1-877-407-9716), Reino Unido (0 800 756 3429) o marcación internacional (1-201-493-6779). Habrá una transmisión en vivo por audio webcast y una repetición estará disponible hasta el 30 de mayo de 2025.
VolitionRx Limited (NYSE AMERICAN: VNRX)는 2025년 5월 16일 금요일 오전 8시 30분(미국 동부 시간)에 2025년 1분기 실적 컨퍼런스 콜 및 사업 업데이트를 예정하고 있습니다. 이번 콜은 루이즈 배첨러(그룹 최고 마케팅 및 커뮤니케이션 책임자), 카메론 레이놀즈(그룹 사장 겸 CEO), 테리그 휴즈(그룹 CFO)가 진행합니다.
컨퍼런스 콜에서는 2025년 1분기 재무 및 운영 실적, 최근 주요 이벤트, 향후 주요 일정에 대해 논의할 예정입니다. 참가자들은 미국 및 캐나다 무료 전화(1-877-407-9716), 영국 무료 전화(0 800 756 3429), 국제 전화(1-201-493-6779) 등 다양한 채널을 통해 참여할 수 있습니다. 라이브 오디오 웹캐스트가 제공되며, 재청취는 2025년 5월 30일까지 가능합니다.
VolitionRx Limited (NYSE AMERICAN : VNRX) a programmé sa conférence téléphonique sur les résultats du premier trimestre 2025 et une mise à jour commerciale pour le vendredi 16 mai 2025 à 8h30, heure de l'Est des États-Unis. L'appel sera animé par Louise Batchelor (Directrice Marketing et Communications du Groupe), Cameron Reynolds (Président et PDG du Groupe) et Terig Hughes (Directeur Financier du Groupe).
La conférence téléphonique portera sur les résultats financiers et opérationnels du premier trimestre 2025, les événements récents importants et les prochaines étapes. Les participants pourront se joindre via plusieurs canaux, y compris les numéros verts pour les États-Unis et le Canada (1-877-407-9716), le Royaume-Uni (0 800 756 3429) ou les appels internationaux (1-201-493-6779). Une diffusion audio en direct sera disponible, et un replay sera accessible jusqu'au 30 mai 2025.
VolitionRx Limited (NYSE AMERICAN: VNRX) hat seine Telefonkonferenz zur Bekanntgabe der Ergebnisse für das erste Quartal 2025 und ein Geschäftsupdate für Freitag, den 16. Mai 2025, um 8:30 Uhr US-Ostküstenzeit angesetzt. Die Telefonkonferenz wird von Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (Präsident und Group CEO) und Terig Hughes (Group CFO) geleitet.
In der Telefonkonferenz werden die finanziellen und operativen Ergebnisse des ersten Quartals 2025, kürzliche wichtige Ereignisse sowie bevorstehende Meilensteine besprochen. Teilnehmer können über verschiedene Kanäle teilnehmen, darunter gebührenfreie Nummern für die USA und Kanada (1-877-407-9716), Großbritannien (0 800 756 3429) oder internationale Einwahlnummern (1-201-493-6779). Eine Live-Audio-Webcast wird verfügbar sein, und eine Aufzeichnung ist bis zum 30. Mai 2025 abrufbar.
- None.
- None.
Conference call to take place on Friday, May 16 at 8:30 a.m.
Event: VolitionRx Limited First Quarter 2025 Earnings and Business Update Conference Call
Date: Friday, May 16, 2025
Time: 8:30 a.m.
Toll/International: 1-201-493-6779
Conference ID: 13753885
Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition and Terig Hughes, Group Chief Financial Officer. The call will provide an update on important events that have taken place in the first quarter of 2025 and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until May 30, 2025. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Investor Relations
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-first-quarter-2025-earnings-conference-call-and-business-update-302452316.html
SOURCE VolitionRx Limited
FAQ
When is VolitionRx (VNRX) reporting Q1 2025 earnings?
How can I listen to VNRX's Q1 2025 earnings call?
Who will host VolitionRx's Q1 2025 earnings call?
Until when will VNRX's Q1 2025 earnings call replay be available?
